Alprolix

Indicated For

Hemophilia B

About This Medication

# HemAssist Patient Assistance Program Patient Guide: How to Get Alprolix (eftrenonacog alfa) at Low or No Cost Alprolix (eftrenonacog alfa) is a prescription medication used to control and prevent bleeding episodes in adults and children with hemophilia B, a rare blood disorder caused by a deficiency in clotting factor IX. The **HemAssist Patient Assistance Program** from **Sanofi** provides **Alprolix at no cost** to eligible patients who are uninsured, underinsured, or facing temporary loss of insurance, including those with government insurance like Medicare or Medicaid.[1][2][3] This guide explains everything you need to know about qualifying for the program, applying, and getting your medication. It's designed to make the process simple and stress-free, so you can focus on your health. ## About Alprolix and Hemophilia B **Alprolix** is a recombinant coagulation Factor IX concentrate with a prolonged half-life, meaning it stays in your body longer than standard Factor IX treatments. This allows for fewer infusions—typically once weekly for routine prophylaxis to prevent bleeding, or on-demand to treat bleeds.[1][3] It's FDA-approved for hemophilia B patients of all ages, helping reduce bleeding frequency and improve quality of life. Hemophilia B affects about 1 in 25,000 males, but can occur in anyone. Symptoms include easy bruising, prolonged bleeding, and joint damage from repeated bleeds. Alprolix helps replace the missing clotting factor, enabling normal blood clotting.[1] If your doctor prescribes Alprolix, HemAssist supports you from enrollment through ongoing care, including benefits investigations, specialty pharmacy coordination, and infusion training.[1][5] ## Who Qualifies for HemAssist Patient Assistance? The program is for patients who need help affording Alprolix due to financial or insurance challenges. Key eligibility: - **Uninsured or underinsured** patients. - Those with **temporary loss of insurance**. - Patients with **government insurance**, including **Medicare, Medicaid, or Marketplace plans**.[1][2][3] - Claims cannot be submitted to third-party payers (private or public insurance) for reimbursement through this program.[2] **Income eligibility**: Specific income thresholds (e.g., Federal Poverty Level percentages) are not publicly detailed; eligibility is determined case-by-case during enrollment. Contact HemAssist for personalized assessment—no strict FPL limits listed.[1][2] | Household Size | Income Threshold | Notes | |---------------|------------------|-------| | Individual | Not specified | Case-by-case review; call for details | | Couple | Not specified | Includes government insurance | | Family of 3 | Not specified | Uninsured/underinsured prioritized | | Family of 4+ | Not specified | Temporary coverage loss eligible | *Table based on program notes; exact limits vary. Always verify with HemAssist.[1][2]* ## Insurance Requirements HemAssist Patient Assistance is flexible: - **Commercial/private insurance**: May qualify if underinsured (high copays/deductibles), but **Copay Assistance Program** (separate) is for commercial plans only—**not** for government insurance.[2][3][7] - **Government insurance (Medicare, Medicaid, Marketplace)**: **Eligible** for Patient Assistance to cover out-of-pocket costs. No reimbursement claims to these payers.[2][3] - **No insurance or temporary lapse**: Fully eligible for free medication.[1] **Important**: This program differs from the Copay Program, which excludes Medicare/Medicaid. Patient Assistance fills that gap.[2][3] ## Step-by-Step Application Process Applying is straightforward with **multiple methods**. Start by calling **(833) 723-5463** (Mon-Fri, 8 AM-7 PM ET) for help from a Case Manager.[1][3][5] 1. **Get your prescription**: Ask your doctor for a valid Alprolix prescription. They can download forms from HemAssist sites.[6][7] 2. **Enroll**: - Call (833) 723-5463 to start verbally. - Visit SanofiHemAssist.com to enroll online or download forms.[2][8] - Your doctor/HCP can submit on your behalf.[1] 3. **Submit required documents**: - **Prescription** from your healthcare provider. - **Proof of income** (e.g., tax returns, pay stubs, W-2s). - **Proof of residency** (e.g., utility bill, lease). - **Proof of insurance status** (insurance card, denial letter, or statement of no coverage).[1][2] 4. **Benefits investigation**: HemAssist verifies coverage and eligibility quickly.[1] 5. **Approval**: If approved, medication ships **directly to you** via specialty pharmacy.[1] HemAssist handles triaging to pharmacies, shipments, and claims support.[1] ## Timeline and Delivery - **Processing time**: Not specified, but enrollment triggers fast benefits check. Free Trial (first 30-day supply) ships in **24-48 hours**—Patient Assistance follows similar speed.[3] - **Delivery**: Shipped free to your home. Case Managers coordinate.[1][5] - **Reauthorization**: **Required** periodically—your doctor resubmits proof of ongoing need.[1] Expect ongoing support, including refill reminders and education.[4][5] ## If Denied or Need Alternatives - **Appeal**: Contact HemAssist immediately—Case Managers review and assist.[1] - **Other options**: - **Copay Program** for commercial insurance (as low as $0).[3][7] - **Free Trial** for first-time users (one-time, 30 days).[2][3] - State programs, nonprofits like Patient Access Network (PAN), or hemophilia organizations. - **No biosimilars** listed for Alprolix.[1] - Switch treatments? Discuss with your doctor; HemAssist supports other Sanofi products.[4] ## Disclaimer This guide is for informational purposes based on publicly available program details as of latest updates. Eligibility, terms, and availability can change. Sanofi reserves the right to modify/terminate programs without notice. Not valid where prohibited by law. Always contact HemAssist at (833) 723-5463 or visit SanofiHemAssist.com for current info, personalized eligibility, and full terms. Consult your doctor before starting/stopping Alprolix. Does not guarantee coverage.[1][2][3] *Word count: ~950*

Program information last verified: March 30, 2026